Eli Lilly and Company (LLY)vsSenti Biosciences Inc (SNTI)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
SNTI
Senti Biosciences Inc
$0.98
-0.86%
HEALTHCARE · Cap: $30.66M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 190128847% more annual revenue ($72.25B vs $38,000). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SNTI
Avoid14
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SNTI
SNTI has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SNTI
The primary concerns for SNTI are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.46 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while SNTI is a value play — different risk/reward profiles.
SNTI carries more volatility with a beta of 2.09 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 14/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Senti Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Senti Biosciences Inc (SNTI) is a cutting-edge biotechnology firm focused on advancing synthetic biology through its proprietary GeneCircuit platform, which enables the creation of programmable cell and gene therapies. The company is dedicated to addressing various diseases, including cancer and genetic disorders, with a strong emphasis on personalized medicine. Senti's promising development pipeline, combined with strategic partnerships, positions it well to lead the innovation of engineered cell therapies and provide transformative solutions to meet significant unmet medical needs within the biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?